Sign in

RGNT on NYSE

REGENTIS BIOMATERIALS LTD.

REGENTIS BIOMATERIALS LTD. is an orthopedic company, listed on NYSE (RGNT).1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$13.6MNet income, fiscal 20252

Compare with another stock.

  • TickerRGNT on NYSE1
  • IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies1
  • HeadquartersL31
  • Incorporated inIsrael3
  • Business address12 Ha'Ilan Street, Northern Industrial, Zone, P.O. Box 260, Or Akiva3
  • Filer categoryNon-accelerated filer, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

GelrinC, we aim to bring to market a product for the therapy of an unmet need for the large market of cartilage injuries in the knee.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-287.7%Return on equity2

Financial statements

Operating income2-$7.0M in 2025+261% since 2023
-$8.0M-$6.0M-$4.0M-$2.0M0$2.0M2023: -$1.9M-$1.9M20232024: $932.0K$932.0K20242025: -$7.0M-$7.0M2025
Net income2-$13.6M in 2025+230% since 2023
-$15.0M-$10.0M-$5.0M0$5.0M2023: -$4.1M-$4.1M20232024: $4.8M$4.8M20242025: -$13.6M-$13.6M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Horizon 2020 grant$2.3M
Research and development expenses-$331.0K-$662.0K-$806.0K
Research and development expenses, net-$331.0K$1.6M-$806.0K
General and administrative expenses-$6.6M-$712.0K-$1.1M
Operating profit (loss)-$7.0M$932.0K-$1.9M
Change in fair value of convertible notes-$4.9M$3.5M-$2.0M
Changes in fair value of warrant liability$160.0K$463.0K$62.0K
Other financing expense, net-$1.9M-$77.0K-$244.0K
Financial income (expense), net-$6.7M$3.9M-$2.2M
Net income (loss) and comprehensive income (loss)-$13.6M$4.8M-$4.1M
Basic net income (loss) per share-$24.16$1.72-$24.09
Dilutednet income (loss) per share-$24.16$1.72-$24.09
Weighted average number of ordinary shares used in computing basic566.7K shares2.8M shares173.5K shares
Weighted average number of ordinary shares used in computing diluted566.7K shares2.8M shares173.5K shares

Compare REGENTIS BIOMATERIALS LTD. with another company

Corporate structure

REGENTIS BIOMATERIALS LTD. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of REGENTIS BIOMATERIALS LTD.

  • Rosalind Advisors, Inc. Filed SCHEDULE 13G on REGENTIS BIOMATERIALS LTD., latest Aug 13, 2026
  • Ehud Geller Filed SCHEDULE 13G on REGENTIS BIOMATERIALS LTD., latest Feb 17, 2026
  • REGENTIS BIOMATERIALS LTD. L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What REGENTIS BIOMATERIALS LTD. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.4M2 Dec 31, 2025

Leadership

Who has led REGENTIS BIOMATERIALS LTD., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ehud Geller2026–now

Chief financial officer

  1. Ori Gon2026–now
  • Chief executive officerEhud Geller Mar 18, 2026 to now5
  • Chief financial officerOri Gon Mar 18, 2026 to now6
Board members and other officers (8)

Timeline

  1. Mar 18, 2026New chief executive Ehud Geller becomes CEO5

Filings

93 filings to the SEC since October 2021: 2 annual reports, 15 insider forms, 2 large holders, 1 private raises, 73 other. The latest 20:

  1. Oct 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Sep 22, 2026EFFECT EDGAR
  3. Sep 17, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 EDGAR
  4. Sep 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Aug 13, 2026SCHEDULE 13G EDGAR
  6. Aug 11, 2026S-8 REGISTRATION STATEMENT EDGAR
  7. Jul 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  8. Jul 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. Jul 13, 2026EFFECT EDGAR
  10. Jul 13, 20264 EDGAR
  11. Jul 13, 2026424B3 PROSPECTUS EDGAR
  12. Jul 13, 20264 EDGAR
  13. Jul 13, 20264 EDGAR
  14. Jul 13, 20264 EDGAR
  15. Jul 13, 20264 EDGAR
  16. Jul 13, 20264 EDGAR
  17. Jul 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Jul 8, 2026F-1 REGISTRATION STATEMENT EDGAR
  19. Jul 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. Jun 25, 2026D EDGAR

The 93 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$6.5M 2026–2026
Money received by yearMoney received by year, 2026–2026: $6.5M in all. Private raises (Form D) $6.5M.$0$2M$4M$6M$8M2026 · Private raises (Form D): $6.5M2026
Figures by year
YearPrivate raises (Form D)Total
2026$6.5M$6.5M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jun 17, 2026Raised $6.5 million in a private offering of equity16 Form D: 22 investors so far Form D

SEC filer profile

How REGENTIS BIOMATERIALS LTD. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARREGENTIS BIOMATERIALS LTD.1
  • CIK0001912966
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company4
  • Incorporated inIsrael4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address12 Ha'Ilan Street, Northern Industrial, Zone, P.O. Box 260, Or Akiva, Israel1
  • Phone306001
  • Shares outstanding5,179,378 shares as of Dec 31, 20254
  • AuditorBrightman Almagor Zohar & Co., Tel Aviv, Israel PCAOB ID 1197; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMar 29, 20221
  • Filings93 in all: 6-K (19), CORRESP (10), 3 (9), F-1/A (9), 4 (6), DRS/A (5), UPLOAD (5), DRS (4)1
    All 23 form types

    F-1 (4), FWP (4), 424B3 (2), DRSLTR (2), EFFECT (2), RW (2), SCHEDULE 13G (2), 20-F (1), 20-F/A (1), 6-K/A (1), 8-A12B (1), CERT (1), D (1), POS AM (1), S-8 (1)

  • Latest filingsAnnual report (20-F) Feb 24, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary shares, no par valueRGNTNYSE American, LLC

From the cover page of the 20-F filed Feb 24, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16